Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for Children With NCOR Gene Mutations
NCT06678685Phase 3Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of spironolactone in Autism Spectrum Disorder (ASD), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Wechsler Intelligence Scale for Children, Fourth Edition at 45 days and Autism Diagnostic Observation Scale-2 at 45 days. Started Oct 2024; status: recruiting.
02
Drugs
spironolactone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06678685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678685.